Does Humana Cover Eliquis?

How Humana Lists Eliquis on Its Formulary

Humana organizes covered drugs into tiers that determine how much you pay at the pharmacy. Eliquis appears on the majority of Humana commercial and Medicare Part D formularies, but the tier placement varies by plan year and region. Brand-name Eliquis most often sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), which carries higher cost-sharing than generic medications on Tier 1 or Tier 2.

Formulary placement matters because it directly sets your copay or coinsurance percentage. A Tier 3 drug on a typical Humana commercial PPO might cost $50 to $80 per fill, while a Tier 4 drug could run $80 to $100 or more. These numbers shift each January when Humana publishes updated formularies. The FDA approved apixaban (brand name Eliquis) in December 2012 for stroke prevention in non-valvular atrial fibrillation, and the drug has since gained additional indications for venous thromboembolism treatment and surgical prophylaxis [1]. Because apixaban is considered a first-line anticoagulant by major cardiology guidelines, Humana rarely excludes it from formulary entirely.

To verify your plan's current tier, log into MyHumana or call the member services number on the back of your insurance card. Formulary search tools on Humana's website let you enter "apixaban" or "Eliquis" and see the exact tier, any quantity limits, and whether prior authorization applies.

What You Will Pay Out of Pocket

The gap between Eliquis's retail price and what you actually pay depends on your deductible status, plan tier, and whether you fill at a preferred pharmacy. Without any insurance, brand-name Eliquis costs roughly $580 to $630 for 60 tablets (a 30-day supply of the standard 5 mg twice-daily dose). That number makes it one of the most expensive maintenance medications many patients take.

On a Humana commercial plan with Tier 3 placement, expect a copay between $35 and $80 per month after meeting your annual deductible. Plans that place Eliquis on Tier 4 often use coinsurance instead of a flat copay, meaning you pay a percentage (commonly 25% to 33%) of the drug's negotiated price. That coinsurance structure can push monthly costs above $100 before any manufacturer discounts apply. A 2023 analysis published in the Journal of the American Heart Association found that out-of-pocket costs for direct oral anticoagulants (DOACs) remain a significant barrier to medication adherence, with average annual patient spending on brand-name DOACs exceeding $1,200 across commercial plans [2].

For patients on Humana Medicare Advantage with prescription drug coverage (MAPD) or standalone Part D, the math changes during each coverage phase. In the initial coverage phase, you pay your plan's standard copay or coinsurance. Once total drug costs hit the coverage-gap threshold ($5,490 in 2026), manufacturer discounts and plan contributions reduce your share. After reaching the catastrophic phase ($8,000 in true out-of-pocket spending for 2026), your cost drops to either 5% coinsurance or a small copay, whichever is greater [3].

Prior Authorization and Quantity Limits

Most Humana plans do not require prior authorization for Eliquis when prescribed for its FDA-approved indications, which include stroke prevention in atrial fibrillation, DVT and PE treatment, and post-surgical thromboprophylaxis [1]. Prior authorization requests, when they do occur, typically arise with off-label dosing or when a plan's step-therapy protocol requires documentation that the patient tried warfarin first.

Quantity limits are more common than prior authorization. Humana frequently caps Eliquis fills at 60 tablets per 30 days, matching the standard twice-daily dosing schedule. If your physician prescribes a higher quantity (for example, during the initial 7-day loading phase of 10 mg twice daily for acute VTE treatment), the pharmacy may need to process an override. Your prescriber's office can submit this electronically, and approval usually takes 24 to 72 hours.

Step therapy is uncommon for Eliquis on Humana plans, partly because the 2019 AHA/ACC/HRS Focused Update on atrial fibrillation management gives DOACs a Class I recommendation over warfarin for most eligible patients with non-valvular AF [4]. The guideline writing committee stated: "In patients with AF who are appropriate for anticoagulation with a DOAC, a DOAC is recommended over warfarin" [4]. That strong endorsement makes it difficult for insurers to mandate warfarin as a prerequisite.

Why Physicians Prescribe Eliquis Over Warfarin

Coverage questions are understandable given the price difference. Generic warfarin costs $4 to $15 per month. But clinical evidence consistently favors apixaban in head-to-head comparisons.

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily with dose-adjusted warfarin in patients with atrial fibrillation and at least one additional stroke risk factor. At a median follow-up of 1.8 years, apixaban reduced stroke or systemic embolism by 21% (hazard ratio 0.79, 95% CI 0.66 to 0.95, P=0.01), lowered major bleeding by 31% (HR 0.69, P<0.001), and cut all-cause mortality by 11% (HR 0.89, P=0.047) compared with warfarin [5]. Dr. Christopher Granger, the trial's lead investigator at Duke University Medical Center, noted that "apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality" [5].

The AMPLIFY trial (N=5,395) showed similar safety advantages in venous thromboembolism treatment. Apixaban was non-inferior to conventional therapy (enoxaparin followed by warfarin) for recurrent VTE, while causing 69% less major bleeding (relative risk 0.31, 95% CI 0.17 to 0.55, P<0.001) [6]. These bleeding reductions translate to fewer emergency department visits, fewer hospitalizations, and lower total cost of care over time, a factor that Humana's pharmacy benefit managers weigh when setting formulary tier placement.

Generic Apixaban and Its Impact on Humana Coverage

The availability of generic apixaban is the single largest factor likely to reduce what Humana members pay for this medication. Bristol-Myers Squibb and Pfizer's key U.S. patents on apixaban have faced challenges from multiple generic manufacturers, and the FDA has granted tentative approvals for generic versions [7]. As generics enter the market, Humana can shift them to lower formulary tiers (Tier 1 or Tier 2), dropping copays to the $5 to $25 range typical of preferred generics.

When a generic becomes available on your Humana plan, your pharmacy will automatically substitute it unless your physician writes "dispense as written." The active ingredient is identical. The FDA requires generic drugs to demonstrate bioequivalence to the brand-name product, meaning the same amount of active drug reaches the bloodstream in the same timeframe [7]. There is no clinically meaningful difference in efficacy or safety between brand-name Eliquis and FDA-approved generic apixaban.

Check your Humana formulary periodically, because generic tier placement can change mid-year when new generics launch. Your pharmacist can also run a "test claim" to see what your plan currently charges for generic apixaban versus brand Eliquis.

Patient Assistance and Copay Reduction Programs

Even with Humana coverage, Eliquis copays can strain a household budget. Several programs exist to lower or eliminate your out-of-pocket cost.

The Eliquis 360 Support Program from Bristol-Myers Squibb offers a copay savings card for commercially insured patients. Eligible individuals pay as little as $10 per month for a 30-day supply, with the manufacturer covering the remainder up to a specified annual maximum. This card does not apply to government-funded insurance (Medicare, Medicaid, Tricare, VA). A real-world study in Circulation: Cardiovascular Quality and Outcomes found that copay assistance programs for DOACs improved 12-month medication adherence by 15 percentage points compared with patients without assistance (76% vs. 61% proportion of days covered, P<0.001) [8].

For Humana Medicare members, manufacturer copay cards are prohibited by federal anti-kickback statutes. Alternative options include:

• Extra Help (Low-Income Subsidy): Qualifying Medicare beneficiaries with limited income and resources can receive premium and copay subsidies through the Social Security Administration. Monthly drug copays drop to $4.50 for generics and $11.20 for brand-name drugs in 2026 [3].
• State Pharmaceutical Assistance Programs (SPAPs): Several states run programs that supplement Medicare Part D coverage. Eligibility criteria and benefits vary by state.
• Humana's own Rx Savings Program: Some Humana Medicare Advantage plans include a supplemental drug benefit that lowers copays on select Tier 3 and Tier 4 medications during the initial coverage phase.

Contact Humana at 1-800-457-4708 to ask about plan-specific discount programs. Your prescriber's office may also have samples or knowledge of local charitable organizations that help with prescription costs.

Comparing Eliquis With Other Covered Anticoagulants on Humana

Eliquis is not the only DOAC on Humana formularies. Xarelto (rivarelbaan), Pradaxa (dabigatran), and Savaysa (edoxaban) may occupy different tiers, and their copay structures can differ from Eliquis. Your physician selects among these based on your diagnosis, kidney function, bleeding risk, and drug interactions, not solely on insurance cost.

A network meta-analysis published in The BMJ compared all four DOACs against warfarin and against each other in atrial fibrillation. Apixaban showed the most favorable balance of efficacy and safety, with the lowest rates of major bleeding among the DOACs while maintaining comparable stroke prevention [9]. The 2023 ACC Expert Consensus Decision Pathway on anticoagulation recommended apixaban or rivaroxaban as first-line options for most patients with non-valvular AF, while noting that apixaban's twice-daily dosing and lower bleeding risk make it preferred for patients at elevated hemorrhagic risk [10].

If your Humana plan places Eliquis on a higher tier than another DOAC, talk with your physician before switching. Dose adjustments differ between DOACs, renal monitoring thresholds are not interchangeable, and some patients on stable apixaban therapy face increased thromboembolic risk during transitions. A cost-driven switch should only happen with your prescriber's direct input.

How to Check and Appeal Your Coverage

Verifying your Eliquis coverage takes about 10 minutes. Here is a step-by-step approach:

1. Log into MyHumana and manage to "Pharmacy" or "Drug Coverage."
2. Enter "apixaban" or "Eliquis" in the formulary search tool.
3. Note the tier, any quantity limits, and whether prior authorization is listed.
4. Check whether generic apixaban appears separately, possibly on a lower tier.
5. Use the "Estimate Drug Cost" feature to see your projected copay at preferred pharmacies.

If Humana denies coverage or places Eliquis at a tier you consider unreasonably expensive, you have the right to request a formulary exception. Your physician must submit a letter of medical necessity explaining why Eliquis is required over lower-tier alternatives. The Centers for Medicare & Medicaid Services (CMS) mandates that Medicare Part D plans respond to standard exception requests within 72 hours and expedited requests within 24 hours [3]. Commercial plan timelines vary but are typically 5 to 15 business days.

A denial can be appealed. First-level appeals go to Humana's internal review. If denied again, Medicare beneficiaries can escalate to an Independent Review Entity (IRE). According to CMS data, approximately 60% of Part D coverage determination appeals are decided in the beneficiary's favor at the first level of review [3].

When Your Plan Changes and What to Watch For

Humana updates its formulary annually, and sometimes mid-year. A drug that was Tier 3 in January could move to Tier 4 in July if the plan renegotiates rebate contracts, or drop to Tier 2 if a generic enters the market. Each change triggers a required written notice to affected members at least 30 days in advance for Medicare plans.

Watch your mail and MyHumana messages in October and November. That is when Humana publishes its Annual Notice of Changes (ANOC) for Medicare plans taking effect the following January. If Eliquis moves to a less favorable tier or gets removed from formulary, you have the Medicare Open Enrollment Period (October 15 through December 7) to switch to another Part D plan that covers it at a lower cost. Tools like the Medicare Plan Finder on Medicare.gov let you compare Eliquis costs across every Part D plan in your ZIP code.

For commercial Humana members, open enrollment through your employer is the equivalent window. Request a copy of the next year's formulary from your HR department before making plan selections.

Patients filling Eliquis at 5 mg twice daily (the standard AF dose) should confirm their plan covers the 5 mg tablet specifically, as the 2.5 mg tablet (used in VTE prophylaxis and for patients meeting dose-reduction criteria based on age ≥80, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL) may have separate coverage terms [1].